←
Every Cure461 posts
Every Cure avatar

Every Cure

@EveryCure

We leverage #ai to unlock the power of each and every drug to treat each and every potential disease they possibly can. Inspired by @DavidFajgenbaum

◷ Joined September 2022▧ 112 Photos and videos
OpenEvidence avatar
⟳ Every Cure retweeted
OpenEvidence@OpenEvidence·Nov 16

The drug that saved @DavidFajgenbaum's life has been on pharmacy shelves for decades. It was approved for kidney transplants. He nearly died of Castleman disease and had been told there was nothing left to try. Thousands of diseases have no FDA-approved treatment. For some of them, the answer may already be sitting in a pharmacy. Nobody has run the trial. @EveryCure, the nonprofit he co-founded, exists to run these trial. Starting today, we’re working with them. OpenEvidence will help evaluate repurposing hypotheses, connect each program with the few physicians who actually treat the disease, and bring trial results back to the point of care when they land. Many of these are generic drugs. No one has a commercial reason to study them. That is exactly why a nonprofit has to.

Post attachment
CBS Mornings avatar
⟳ Every Cure retweeted
CBS Mornings@CBSMornings·Nov 12

Dr. @DavidFajgenbaum’s hope to find treatments for up to 25 diseases in the coming years using AI began with his own quest to treat himself, when he was diagnosed with a rare and life-threatening disease while in medical school. Dr. David Fajgenbaum shares about his nonprofit, @EveryCure, and how he’s using artificial intelligence as a tool to treat rare diseases.

4:43
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·8 Sep 2025

15 years ago I said goodbye to my friends and family because I thought I wouldn’t survive… Today our TED talk goes live that could help us save patients. You can click this link to watch the full talk: go.ted.com/davidfajgenbaum Please watch, like, repost, and share the talk as far and wide as you can to help us on our mission to save and improve lives by repurposing drugs!

0:56
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·20 Mar 2025

We are thrilled to share that the @nytimes has just featured @EveryCure and our work using repurposed drugs to save lives. Click the link below to read the full article! nytimes.com/2025/03/20/well/…

CBS Evening News with Tony Dokoupil avatar
⟳ Every Cure retweeted
CBS Evening News with Tony Dokoupil@CBSEveningNews·18 Feb 2025

Doctors are studying the low-cost drug leucovorin, derived from folic acid, as a possible treatment for autism in children. But with little profit potential, pharmaceutical companies won’t fund FDA trials — leaving families dependent on off-label prescriptions. Dr. @celinegounder reports.

3:21
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·6 Feb 2025

Thrilled to share that our work has just been published in the @NEJM highlighting a life saved with a repurposed drug, adalimumab. nejm.org/doi/full/10.1056/NE… Through proteomics and cellular assays in my lab at @PennMedicine, we identified TNF signaling as a key driver of Castleman disease. Concurrently, @EveryCure’s AI platform independently predicted that a TNF inhibitor could be a top treatment. When a patient was on the verge of being transferred to hospice, we recommended administering adalimumab—and it saved his life. Two years later, he remains in remission, thriving on a drug that was never originally intended for his condition. #MedTwitter

Post attachment
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·23 Jan 2025

What if a common amino acid found at your local health store could alleviate some of the worst pain imaginable for sickle cell patients? Patients with sickle cell disease often endure severe, life-limiting pain from vaso-occlusive crises caused by sickled red blood cells. Research, however, suggests that arginine, a common amino acid, could offer relief. By dilating blood vessels and improving blood flow, arginine has the potential to prevent these crises and reduce pain. While the research is still early, with only a few clinical trials conducted, the data is incredibly promising. This is exactly why @EveryCure exists: to uncover hidden treatments for devastating conditions and bring hope to those who need it most. #MedTwitter

0:31
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·18 Dec 2024

Did you know a simple derivative of vitamin C is transforming the lives of children with congenital disorders of glycosylation? This breakthrough, led by Dr. @eperlste and the CDG Cure Collective is helping kids experience fewer seizures and improved symptoms—an incredible leap forward for CDG patients and their families. Seeing the before-and-after videos of children who have benefited from this treatment is nothing short of inspiring. These moments remind us why innovation and collaboration in rare disease research are so vital. #MedTwitter

0:33
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·11 Dec 2024

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions  with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

0:50
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·5 Dec 2024

What if a simple, affordable drug could unlock communication skills for children with autism? A significant number of children with autism may have cerebral folate deficiency due to auto-antibodies against the folate receptor, effectively blocking folate from reaching the brain.  However, high-dose leucovorin, an old and inexpensive drug, can bypass this issue by delivering folinic acid through an alternative pathway, restoring functional folate levels in the brain. Three randomized controlled trials have already demonstrated that leucovorin improves verbal communication and other symptoms in children with autism.  Yet, despite its potential, this promising treatment remains underutilized—largely because it's an inexpensive, older drug, and our current system lacks a viable path to repurpose such drugs for new indications. It's a powerful reminder of the urgent need to rethink how we prioritize and adopt therapies for unmet medical needs. #MedTwitter

0:38
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·15 Nov 2024

I'm thrilled to announce that I'm hiring a Chief of Staff to work as my right-hand person across the three incredible organizations I lead. The official title is Director of Strategy and Business Development, and I’m on the lookout for someone: 🧬 Hungry to make an impact
🧬With a strategic mindset
🧬Backed by biomedical experience—whether that’s in the pharmaceutical industry, a master’s program, a PhD, or beyond This role is perfect for someone ready to dive deep into transformative work and help drive innovation at the intersection of science, strategy, and impact. Click the link below to apply! linkedin.com/jobs/view/40646…

0:24
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·30 Oct 2024

Injecting lidocaine directly into breast cancer tumors resulted in a remarkable 29% reduction in mortality, according to a large randomized control trial involving nearly 1,600 patients! Researchers estimate that this simple, accessible approach could save over 100,000 lives worldwide if widely adopted. As we observe Breast Cancer Awareness Month this October, it’s important to spotlight promising discoveries like this. What's even more exciting is that because similar receptors are present in other cancers, lidocaine could potentially be effective for more than just breast cancer. This is exactly why @EveryCure exists—to match affordable, old drugs like lidocaine with devastating diseases like cancer, ensuring that every patient can benefit from lifesaving treatments.

0:42
David Fajgenbaum, MD avatar
⟳ Every Cure retweeted
David Fajgenbaum, MD@DavidFajgenbaum·28 Oct 2024

It was an incredible honor to accept the Vision of Hope Award at the 2024 Stand Up to Sarcoma Gala on behalf of my teams at @PennMedicine, @CureCastleman, and @EveryCure. Angiosarcoma hits especially close to home for me and my family, as my uncle was diagnosed with this devastating disease and given a grim prognosis. Fortunately, we were able to repurpose a drug that had never been used for his condition before—and it saved his life. Now, after 8 years of remission, I had the privilege of watching him walk his son (my cousin) down the aisle at his wedding just a few weeks ago. Moments like these remind me why we do what we do. At Every Cure, we’re committed to finding more life-saving opportunities like this one so patients like my uncle aren’t told, ‘we’ve tried everything’ when there’s a life-saving cure sitting on the pharmacy shelves.

5:00
Matthew Herper avatar
⟳ Every Cure retweeted
Matthew Herper@matthewherper·7 Oct 2024

Janet Woodcock, former FDA official, joins board of patient group focused on ‘rediscovering’ old drugs Woodcock + @DavidFajgenbaum = ?????? statnews.com/2024/10/07/jane… via @statnews